It is worth highlighting that ANXA1 and ANXA2 have been linked to radio-chemoresistance and immunosuppression in HNC and other cancers, which poses a plausible application as adjuvant treatments to jointly improve treatment response and antitumor immune response. This evidence concerns the gene ANXA1 and cancer.